Zhaowei Yang

Zhaowei Yang

Auto-generated profile, based on publicly available information

Zhaowei Yang

Department of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
RCRuchong Chen
Ruchong Chen
LSLing Sang
Ling Sang
MJMei Jiang
Mei Jiang
ZYZhaowei Yang
Zhaowei Yang
NJNan Jia
Nan Jia
NZNanshan Zhong
Nanshan Zhong

9 September 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
LFLi Tai Fang
Li Tai Fang
BZBin Zhu
Bin Zhu
YZYongmei Zhao
Yongmei Zhao
WCWanqiu Chen
Wanqiu Chen
ZYZhaowei Yang
Zhaowei Yang
WXWenming Xiao
Wenming Xiao

21 December 2020 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
WCWanqiu Chen
Wanqiu Chen
YZYongmei Zhao
Yongmei Zhao
XCXin Chen
Xin Chen
ZYZhaowei Yang
Zhaowei Yang
XXXiaojiang Xu
Xiaojiang Xu
CWCharles Wang
Charles Wang

5 December 2022 in Allergy
Verified
Journal Article
Open access
HZHuan‐Ping Zhang
Huan‐Ping Zhang
YSYuan‐Li Sun
Yuan‐Li Sun
YWYan‐Fen Wang
Yan‐Fen Wang
DYDuygu Yazici
Duygu Yazici
DADilek Azkur
Dilek Azkur
DGDong Ya Gao
Dong Ya Gao
There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 (COVID‐19) patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID‐19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID‐19. The efficacy of the COVID‐19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4, and BA.5 and the global administration of COVID‐19 vaccines have changed the clinical scenario of COVID‐19. Multisystem inflammatory syndrome in children (MIS‐C) may cause severe and heterogeneous disease but with a lower mortality rate. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long‐term symptoms of COVID‐19. There is conflicting evidence about whether atopic diseases, such as allergic asthma and rhinitis, are associated with a lower susceptibility and better outcomes of COVID‐19. At the beginning of pandemic, the European Academy of Allergy and Clinical Immunology (EAACI) developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID‐19 vaccines and emerging severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID‐19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID‐19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID‐19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS‐CoV‐2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high‐risk groups, the development of MIS‐C and long COVID‐19.

1 January 2013 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
ZGZhong-shan Gao
Zhong-shan Gao
ZYZhao-Wei Yang
Zhao-Wei Yang
SWShan-Dong Wu
Shan-Dong Wu
HWHui-Ying Wang
Hui-Ying Wang
MLMei-Ling Liu
Mei-Ling Liu
RRRonald van Ree
Ronald van Ree

1 October 2017 in Respiratory Medicine
Verified
Journal Article
Open access
NLNaijian Li
Naijian Li
RQRihuang Qiu
Rihuang Qiu
ZYZhaowei Yang
Zhaowei Yang
JLJing Li
Jing Li
KCKian Fan Chung
Kian Fan Chung
QZQingling Zhang
Qingling Zhang
Altered composition of airway microbiota has been reported in subjects suffering from asthma but its relation to eosinophilic phenotype is unclear. To examine the relationship between sputum microbiota, asthma severity and inflammatory type in asthmatic subjects from Guangzhou, China. Induced sputum samples were obtained from 49 non-smoking asthma patients, 25 severe and 24 non-severe, and 15 healthy subjects. Total DNA was amplified using primers specific for the V3-V5 hypervariable region of bacterial 16s rRNA and sequenced using the 454 GS FLX sequencer. Sequences were assigned to bacterial taxa by comparing them with 16s rRNA sequences in the Ribosomal Database Project. Sputum eosinophil counts were higher and FEV1 (% predicted) was lower in severe compared to non-severe asthmatics. There were no significant differences in operational taxonomic unit (OTU) numbers at the phylum level and in diversity scores between non-severe asthmatics and severe asthmatics, and healthy subjects. At the family level, Porphyromonadaceae was most abundant in healthy subjects whereas Pseudomonadaceae and Enterobacteriaceae were higher in severe asthmatics compared to non-severe asthmatics (p < 0.05). Actinomycetaceae was particularly abundant in eosinophilic asthma patients compared to non-eosinophilic asthma (p = 0.011). Bacteroidaceae was positively correlated with FEV1 in all subjects (r = 0.335, p < 0.01), whereas body mass index was negatively associated with the number of species observed (r = -0.3, p < 0.05). Principal component analysis confirmed the positive association of Actinomycetaceae and Enterobacteriaceae abundance with eosinophilic asthma. Patients with asthma have an altered airway microbiota, with specific bacteria associated with severe asthma and the eosinophilic inflammatory phenotype.